This transaction recognizes groundbreaking science originating from French academia," said Pierre d'Epenoux, CEO, ImCheck Therapeutics. Centerview Partners is acting as exclusive financial advisor to ImCheck Therapeutics with Goodwin (London) and Dentons (Paris) acting as legal counsel. About ImCheck TherapeuticsImCheck Therapeutics is developing a new generation of immunotherapeutic antibodies targeting butyrophilins, a novel superfamily of immunomodulators. Use of the words 'believes', 'anticipates' and 'expects' and similar expressions are intended to identify forward-looking statements, including Ipsen's expectations regarding future events, including regulatory filings and determinations. A default by any of Ipsen's partners could generate lower revenues than expected.